Validation of Saliva in the Esoterix Genetic Laboratories Fragile X Assay

Status Not yet recruiting

Clinical Trial Summary

The purpose of this research is to determine if saliva samples can be used as an alternate sample type to test for fragile X. By using saliva instead of blood, it would be easier for patients to have fragile X testing.

Clinical Trial Description

Saliva samples will be prospectively collected from subjects who have previously been tested by Esoterix Genetic Laboratories, LLC using blood specimens and diagnosed as fragile X intermediates, premutations (carriers) or full mutations (affected). Results from fragile X testing with saliva will be compared to results from the blood sample that was previously submitted to Esoterix Genetic Laboratories for testing.

Data from this study will be used for regulatory submissions. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Fragile X Syndrome

Clinical Trial Details

NCT number	NCT01616589
Study type	Observational
Source	Esoterix Genetic Laboratories, LLC
Contact	Naomi Nakata, MA
Phone	310 482-5561
Email	naomi.nakata@integratedgenetics.com
Status	Not yet recruiting
Phase	N/A
Start date	July 2012
Completion date	December 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05418049` - Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge	Phase 2
Enrolling by invitation	`NCT01364818` - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment	N/A
Completed	`NCT00965432` - A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107	Phase 1
Completed	`NCT01120626` - Randomized Controlled Study of Donepezil in Fragile X Syndrome	Phase 2
Completed	`NCT01204151` - Teaching Math Skills to Individuals With Fragile X Syndrome	N/A
Active, not recruiting	`NCT00334971` - Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women	N/A
Enrolling by invitation	`NCT06139172` - Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities	N/A
Recruiting	`NCT04977986` - Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome	Phase 3
Active, not recruiting	`NCT04698551` - NIPD on cffDNA for Triplet Repeat Diseases
Completed	`NCT03722290` - Metformin in Children and Adults With Fragile X Syndrome	Phase 2
Completed	`NCT05030129` - Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Syndrome	Phase 2
Recruiting	`NCT05957549` - Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG	N/A
Recruiting	`NCT04141163` - Metformin in Patients With Fragile X	Phase 1/Phase 2
Not yet recruiting	`NCT06081348` - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders	Phase 2
Completed	`NCT00858689` - Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome	N/A
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Enrolling by invitation	`NCT03802799` - Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS	Phase 2/Phase 3
Recruiting	`NCT05295277` - Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort
Enrolling by invitation	`NCT03836300` - Parent and Infant Inter(X)Action Intervention (PIXI)	N/A
Completed	`NCT01725152` - Ganaxolone Treatment in Children With Fragile X Syndrome	Phase 2